Zobrazit v EDS

Real-World Treatment Patterns and Overall Survival (OS) of Patients with Metastatic Castration-Resistant Prostate Cancer in Italy.

Uloženo v:
Podrobná bibliografie
Název: Real-World Treatment Patterns and Overall Survival (OS) of Patients with Metastatic Castration-Resistant Prostate Cancer in Italy.
Autoři: Dovizio, Melania, Castelletti, Daniela, Luraghi, Paolo, Losi, Serena, Gervasi, Andrea, Risi, Matteo, Leogrande, Melania, Esposti, Luca Degli, Procopio, Giuseppe
Zdroj: Pragmatic & Observational Research; Nov2025, Vol. 16, p189-199, 11p
Témata: CASTRATION-resistant prostate cancer, OVERALL survival, THERAPEUTICS, ANDROGEN receptors, CANCER chemotherapy, MEDICAL databases, ITALIAN history, SCIENTIFIC observation
Geografický termín: ITALY
Abstrakt: Purpose: This real-world analysis described the characteristics and therapeutic management of patients with metastatic castration-resistant prostate cancer (mCRPC) in Italy before and after 2015, when androgen receptor signalling inhibitors (ARPI) entered clinical practice. Patients and Methods: An observational retrospective analysis was conducted using administrative healthcare databases from a pool of Italian Local Health Units, covering ~6.2 million residents. Adult men with ≥ 1 prescription of androgen deprivation therapy (ADT) from January 2011 to June 2022 were identified. mCRPC was proxied by treatment patterns—addition of docetaxel/cabazitaxel or ARPI to ADT—and confirmed by hospital discharge for metastasis. Patients were stratified according to their inclusion (date of the last inclusion criterion met): pre-2015 (2011– 2014) and post-2015 (2015– 2020). Results: Among 1890 mCRPC patients identified, 551 (29%) received ≥ 2 treatment lines. Chemotherapy (CHT) was the predominant first-line (1L) therapy in both cohorts [97.2% vs 82.9%], followed by ARPI [2.8% vs 17.1%]. In a 2020 sensitivity analysis (n=406), 1L therapy was ARPI in 76% and CHT in 24%. Among pre- and post-2015 patients, 29.4% and 31.6% received second-line (2L) therapy, mostly ARPI. Median OS from ADT initiation was 46.4 months (pre-2015) and 53.9 months (post-2015). In post-2015 patients, median OS from mCRPC index-date—reflecting the proxy-based diagnosis—was 14.2 months. Conclusion: In Italian clinical practice, CHT remains the most common 1L therapy though ARPI use has increased since 2015. While OS from ADT initiation has improved, survival from mCRPC diagnosis—based on proxies in administrative data—remains poor, underscoring an unmet clinical need. Differences in OS estimates depending on the starting point (ADT initiation vs mCRPC diagnosis) should be considered when interpreting results. [ABSTRACT FROM AUTHOR]
Copyright of Pragmatic & Observational Research is the property of Dove Medical Press Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Databáze: Biomedical Index
FullText Text:
  Availability: 0
CustomLinks:
  – Url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pmc&term=1179-7266[TA]+AND+189[PG]+AND+2025[PDAT]
    Name: FREE - PubMed Central (ISSN based link)
    Category: fullText
    Text: Full Text
    Icon: https://imageserver.ebscohost.com/NetImages/iconPdf.gif
    MouseOverText: Check this PubMed for the article full text.
  – Url: https://resolver.ebscohost.com/openurl?sid=EBSCO:edm&genre=article&issn=11797266&ISBN=&volume=16&issue=&date=20251101&spage=189&pages=189-199&title=Pragmatic & Observational Research&atitle=Real-World%20Treatment%20Patterns%20and%20Overall%20Survival%20%28OS%29%20of%20Patients%20with%20Metastatic%20Castration-Resistant%20Prostate%20Cancer%20in%20Italy.&aulast=Dovizio%2C%20Melania&id=DOI:10.2147/POR.S539229
    Name: Full Text Finder
    Category: fullText
    Text: Full Text Finder
    Icon: https://imageserver.ebscohost.com/branding/images/FTF.gif
    MouseOverText: Full Text Finder
  – Url: https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=EBSCO&SrcAuth=EBSCO&DestApp=WOS&ServiceName=TransferToWoS&DestLinkType=GeneralSearchSummary&Func=Links&author=Dovizio%20M
    Name: ISI
    Category: fullText
    Text: Nájsť tento článok vo Web of Science
    Icon: https://imagesrvr.epnet.com/ls/20docs.gif
    MouseOverText: Nájsť tento článok vo Web of Science
Header DbId: edm
DbLabel: Biomedical Index
An: 189707814
RelevancyScore: 1082
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 1082.14831542969
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Real-World Treatment Patterns and Overall Survival (OS) of Patients with Metastatic Castration-Resistant Prostate Cancer in Italy.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Dovizio%2C+Melania%22">Dovizio, Melania</searchLink><br /><searchLink fieldCode="AR" term="%22Castelletti%2C+Daniela%22">Castelletti, Daniela</searchLink><br /><searchLink fieldCode="AR" term="%22Luraghi%2C+Paolo%22">Luraghi, Paolo</searchLink><br /><searchLink fieldCode="AR" term="%22Losi%2C+Serena%22">Losi, Serena</searchLink><br /><searchLink fieldCode="AR" term="%22Gervasi%2C+Andrea%22">Gervasi, Andrea</searchLink><br /><searchLink fieldCode="AR" term="%22Risi%2C+Matteo%22">Risi, Matteo</searchLink><br /><searchLink fieldCode="AR" term="%22Leogrande%2C+Melania%22">Leogrande, Melania</searchLink><br /><searchLink fieldCode="AR" term="%22Esposti%2C+Luca+Degli%22">Esposti, Luca Degli</searchLink><br /><searchLink fieldCode="AR" term="%22Procopio%2C+Giuseppe%22">Procopio, Giuseppe</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Pragmatic & Observational Research; Nov2025, Vol. 16, p189-199, 11p
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22CASTRATION-resistant+prostate+cancer%22">CASTRATION-resistant prostate cancer</searchLink><br /><searchLink fieldCode="DE" term="%22OVERALL+survival%22">OVERALL survival</searchLink><br /><searchLink fieldCode="DE" term="%22THERAPEUTICS%22">THERAPEUTICS</searchLink><br /><searchLink fieldCode="DE" term="%22ANDROGEN+receptors%22">ANDROGEN receptors</searchLink><br /><searchLink fieldCode="DE" term="%22CANCER+chemotherapy%22">CANCER chemotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22MEDICAL+databases%22">MEDICAL databases</searchLink><br /><searchLink fieldCode="DE" term="%22ITALIAN+history%22">ITALIAN history</searchLink><br /><searchLink fieldCode="DE" term="%22SCIENTIFIC+observation%22">SCIENTIFIC observation</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22ITALY%22">ITALY</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Purpose: This real-world analysis described the characteristics and therapeutic management of patients with metastatic castration-resistant prostate cancer (mCRPC) in Italy before and after 2015, when androgen receptor signalling inhibitors (ARPI) entered clinical practice. Patients and Methods: An observational retrospective analysis was conducted using administrative healthcare databases from a pool of Italian Local Health Units, covering ~6.2 million residents. Adult men with ≥ 1 prescription of androgen deprivation therapy (ADT) from January 2011 to June 2022 were identified. mCRPC was proxied by treatment patterns—addition of docetaxel/cabazitaxel or ARPI to ADT—and confirmed by hospital discharge for metastasis. Patients were stratified according to their inclusion (date of the last inclusion criterion met): pre-2015 (2011– 2014) and post-2015 (2015– 2020). Results: Among 1890 mCRPC patients identified, 551 (29%) received ≥ 2 treatment lines. Chemotherapy (CHT) was the predominant first-line (1L) therapy in both cohorts [97.2% vs 82.9%], followed by ARPI [2.8% vs 17.1%]. In a 2020 sensitivity analysis (n=406), 1L therapy was ARPI in 76% and CHT in 24%. Among pre- and post-2015 patients, 29.4% and 31.6% received second-line (2L) therapy, mostly ARPI. Median OS from ADT initiation was 46.4 months (pre-2015) and 53.9 months (post-2015). In post-2015 patients, median OS from mCRPC index-date—reflecting the proxy-based diagnosis—was 14.2 months. Conclusion: In Italian clinical practice, CHT remains the most common 1L therapy though ARPI use has increased since 2015. While OS from ADT initiation has improved, survival from mCRPC diagnosis—based on proxies in administrative data—remains poor, underscoring an unmet clinical need. Differences in OS estimates depending on the starting point (ADT initiation vs mCRPC diagnosis) should be considered when interpreting results. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label:
  Group: Ab
  Data: <i>Copyright of Pragmatic & Observational Research is the property of Dove Medical Press Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://erproxy.cvtisr.sk/sfx/access?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edm&AN=189707814
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.2147/POR.S539229
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 11
        StartPage: 189
    Subjects:
      – SubjectFull: ITALY
        Type: general
      – SubjectFull: CASTRATION-resistant prostate cancer
        Type: general
      – SubjectFull: OVERALL survival
        Type: general
      – SubjectFull: THERAPEUTICS
        Type: general
      – SubjectFull: ANDROGEN receptors
        Type: general
      – SubjectFull: CANCER chemotherapy
        Type: general
      – SubjectFull: MEDICAL databases
        Type: general
      – SubjectFull: ITALIAN history
        Type: general
      – SubjectFull: SCIENTIFIC observation
        Type: general
    Titles:
      – TitleFull: Real-World Treatment Patterns and Overall Survival (OS) of Patients with Metastatic Castration-Resistant Prostate Cancer in Italy.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Dovizio, Melania
      – PersonEntity:
          Name:
            NameFull: Castelletti, Daniela
      – PersonEntity:
          Name:
            NameFull: Luraghi, Paolo
      – PersonEntity:
          Name:
            NameFull: Losi, Serena
      – PersonEntity:
          Name:
            NameFull: Gervasi, Andrea
      – PersonEntity:
          Name:
            NameFull: Risi, Matteo
      – PersonEntity:
          Name:
            NameFull: Leogrande, Melania
      – PersonEntity:
          Name:
            NameFull: Esposti, Luca Degli
      – PersonEntity:
          Name:
            NameFull: Procopio, Giuseppe
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: Nov2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 11797266
          Numbering:
            – Type: volume
              Value: 16
          Titles:
            – TitleFull: Pragmatic & Observational Research
              Type: main
ResultId 1